NOVA BONE: Much More Than a Shooting Star! (SpineBlogger)
NovaBone Expands Development Capabilities for Orthopedic and Dental Bioactive Bone Graft Substitutes (press release)
NovaBone Putty MIS, NovaBone. The new system includes a syringe with pre-loaded NovaBone Putty and six millimeter diameter cannulas at varying lengths for bone grafting at the surgical site. The system delivers an osteoconductive matrix to stimulate the osteoblastic activity at the site.JACKSONVILLE, Fla.–(BUSINESS WIRE)–NovaBone Products, LLC announces the opening of a new dedicated Research and Development facility in Gainesville, Florida. NovaBone Products develops bone graft substitutes based on advancements in biomedical engineering that meet the specialized needs of orthopedic and dental surgeons.
“In fact, we have already seen breakthrough progress on key projects with our bioactive bone graft”The new 3,500 square foot facility provides the platform for NovaBone Products to implement its product development strategy and was completed in conjunction with the recent appointment of Gregory Pomrink as Vice President, Research & Development. Prior to joining NovaBone Products, Mr. Pomrink worked at Orthovita, Dentsply and Integra LifeSciences.
“Greg has the perfect background and experience to help NovaBone Products continue to grow sales at 50+% per year,” said Art Wotiz, President. “In fact, we have already seen breakthrough progress on key projects with our bioactive bone graft,” he added.
NovaBone Products has further committed additional staff and equipment for the new facility. “NovaBone has clearly demonstrated its commitment to new product development,” said Greg Pomrink. “I am honored to play a vital role in defining the future achievements of this company through product innovations.”
NovaBone Products, LLC is a leading producer and marketer of bioactive synthetic bone graft substitutes. NovaBone is the pioneer of silicon and calcium ion controlled release products that stimulate and accelerate the regeneration of cortical and cancellous bone. The company markets on a worldwide basis from its offices in Florida, New Jersey, and Shanghai, PRC.
Since its inception in 2002, the company has developed numerous formulations and delivery systems of its patented, bioactive technology platform. The product portfolio stimulates accelerated bone growth for the repair of osseous defects throughout the skeletal system.